GSK seeks approval for diabetes drug albiglutide

01/14/2013 | Reuters

GlaxoSmithKline has filed for FDA approval for albiglutide, its once-weekly diabetes drug. Albiglutide is an injectable GLP-1 drug and belongs to the same class as Novo Nordisk's Victoza and Bristol-Myers Squibb and AstraZeneca's Byetta and Bydureon.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Actuarial Services, Government Programs
PacificSource
Springfield, OR
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC